Meropenem Dosing for Elderly Female with ESRD
For an elderly female with end-stage renal disease (ESRD), administer meropenem 500 mg every 24 hours as a 30-minute intravenous infusion, given after hemodialysis on dialysis days 1.
Dosing Algorithm Based on Renal Function
The FDA-approved dosing for ESRD is clear and should be followed:
- Creatinine clearance <10 mL/min or on hemodialysis: One-half the recommended dose (500 mg for most infections) every 24 hours 1
- Timing: Administer after hemodialysis sessions to prevent premature drug removal and facilitate directly observed therapy 2, 3
Infection-Specific Considerations
For complicated intra-abdominal infections where the standard dose is 1 gram every 8 hours:
- Reduce to 500 mg every 24 hours in ESRD 1
For complicated skin/soft tissue infections where the standard dose is 500 mg every 8 hours:
- Reduce to 250 mg every 24 hours in ESRD 1
If treating Pseudomonas aeruginosa (which normally requires 1 gram every 8 hours):
- Use 500 mg every 24 hours in ESRD, post-dialysis 1
Pharmacokinetic Rationale
Meropenem clearance is almost exclusively renal (approximately 80%), making dose adjustment critical in ESRD 3, 4. The elimination half-life increases dramatically from 0.9-1.5 hours in normal renal function to 6.8-7.0 hours in ESRD 3, 4. Hemodialysis removes approximately 30% of meropenem, shortening the half-life from 7.0 to 2.9 hours during dialysis 3.
Critical Safety Considerations
Seizure risk is a major concern in this population. Even the recommended dose of 500 mg daily may be excessive in elderly patients with low body mass index 5. Monitor closely for:
- Central nervous system toxicity (confusion, tremors, seizures)
- Signs of drug accumulation
- Consider therapeutic drug monitoring if available 2
Additional Elderly-Specific Factors
The elderly have age-related decline in renal function beyond measured creatinine clearance 1. In a 90+ year-old female with low body weight, the Cockcroft-Gault equation may overestimate renal function 6. Do not further reduce the dose below FDA recommendations, but maintain heightened vigilance for adverse effects 7.
Monitoring Parameters
- Baseline: Renal function, neurological status
- During therapy: Daily assessment for CNS symptoms, particularly after doses 5-7 when accumulation risk peaks 5
- Post-dialysis timing: Verify administration occurs after, not before, dialysis sessions 3
Common Pitfalls to Avoid
- Do not use standard dosing (1 gram every 8 hours) in ESRD—this dramatically increases seizure risk 5
- Do not dose before hemodialysis—this wastes drug and may cause underdosing 2, 3
- Do not assume elderly patients need lower doses than FDA recommendations—the half-dose regimen already accounts for reduced clearance 7
- Avoid concomitant valproic acid—carbapenems reduce valproic acid levels and increase seizure risk 2, 1
The evidence strongly supports that meropenem 500 mg every 24 hours post-dialysis provides adequate exposure while minimizing toxicity risk in elderly ESRD patients 1, 3, 4, 7.